newsfilter
← Latest News
PR Newswire·

Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

Peer-reviewed analyses establish baseline plasma DKK1 as a continuous quantitative biomarker predicting deepening sirexatamab benefit in 2L mCRC patients In DKK1-high 2L mCRC patients, sirexatamab improved response,